PDS Biotechnology enters $50M ATM equity offering program with B. Riley and H.C. Wainwright

PDS Biotechnology Corp

New at-the-market sales agreement allows up to $50M in common stock through B. Riley Securities and H.C. Wainwright.
Replaces prior August 2022 ATM program; 3% commission on gross proceeds to agents.
Shares sold via Rule 415 at-the-market on Nasdaq Capital Market; no minimum sales obligation.
Prior ATM agreement with B. Riley and BTIG terminated effective August 13, 2024.
Proceeds from any future sales will be used for general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.